Medpace Holdings, Inc. (MEDP): Operating Cash Flow
$713.22M
Year ended 2025-12-31
$752.66M
Trailing 12 months to 2026-06-30
+22.5%
3-year compound annual growth
+22.5%
5-year compound annual growth
+23.6%
10-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $713.22M | +17.1% | 2026-02-10, From 2025-01-01 |
| 2024-12-31 | $608.82M | +40.5% | 2026-02-10, From 2024-01-01 |
| 2023-12-31 | $433.37M | +11.7% | 2026-02-10, From 2023-01-01 |
| 2022-12-31 | $388.05M | +47.4% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $263.33M | +1.8% | 2024-02-13, From 2021-01-01 |
| 2020-12-31 | $258.68M | +28.1% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $201.87M | +28.9% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $156.58M | +60.8% | 2021-02-16, From 2018-01-01 |
| 2017-12-31 | $97.39M | +6.2% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $91.73M | +6.8% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $85.87M | n/a | 2018-02-27, From 2015-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $713.22M | +17.1% |
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $737.65M | +0.4% |
| Incyte Corp (INCY) | 2025-12-31 | $1.41B | +321.5% |
| Icon PLC (ICLR) | 2025-12-31 | $1.04B | -19.5% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $2.65B | -2.3% |
| NRC Health (NRC) | 2025-12-31 | $26.45M | -23.6% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | -$34.41M | n/m |
| OmniAb, Inc. (OABI) | 2025-12-31 | -$36.45M | n/m |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | -$3.87M | n/m |
Compare MEDP, CRL, INCY, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗